Jump to Content Jump to Main Navigation
HOME BROWSE
CLINICAL RESOURCES DRUG INFORMATION EDUCATION AND TRAINING PHARMACY PRACTICE CAREER DEVELOPMENT
AJHP DRUG INFORMATION PROFESSIONAL DEVELOPMENT
Sign in Sign up
Advanced Search Help
Sign in Sign up
HOME BROWSE
CLINICAL RESOURCES DRUG INFORMATION EDUCATION AND TRAINING PHARMACY PRACTICE CAREER DEVELOPMENT
AJHP DRUG INFORMATION PROFESSIONAL DEVELOPMENT
Advanced Search Help

Cover Clinical Pharmacokinetics
 

 

  • Front Matter
    • Preliminary Material
  • Basic Concepts and Special Populations
    • RATIONAL USE OF DRUG CONCENTRATION MEASUREMENTS
    • ASSESSMENT OF KIDNEY FUNCTION
    • RENAL DRUG DOSING CONCEPTS
    • MEDICATION DOSING IN OVERWEIGHT AND OBESE PATIENTS
    • PHARMACOGENOMIC IMPACTS ON PHARMACOKINETICS
    • DRUG DOSING IN PEDIATRIC PATIENTS
    • CONSIDERATIONS FOR MEDICATION USE IN THE GERIATRIC PATIENT
  • Specific Drugs and Drug Classes
    • AMINOGLYCOSIDES
    • ANTIDEPRESSANTS
    • ANTIEPILEPTICS
    • ANTIREJECTION AGENTS
    • CARBAMAZEPINE
    • DIGOXIN
    • ETHOSUXIMIDE
    • UNFRACTIONATED HEPARIN, LOW-MOLECULAR-WEIGHT HEPARINS, AND FONDAPARINUX
    • LIDOCAINE
    • LITHIUM
    • PHENOBARBITAL
    • PHENYTOIN AND FOSPHENYTOIN
    • THEOPHYLLINE
    • VALPROATE
    • VANCOMYCIN
    • WARFARIN
  • APPENDICES
    • APPENDIX A
    • APPENDIX B
  • Back Matter
    • Index

APPENDIX A

in Clinical Pharmacokinetics
Author:
John E. Murphy
DOI:
https://doi.org/10.37573/9781585286607.024
Restricted access
Email this content

Share Link


Copy this link, or click below to email it to a friend
Email this content
or copy the link directly:
The link was not copied. Your current browser may not support copying via this button.
Link copied successfully

About ASHP Contact Us Correction Notices Customer Relations
FAQs Information for Authors Libraries and Institutions Rights and Permissions

© 2023 American Society of Health-System Pharmacists. All Rights Reserved.

Powered by: PubFactory

Powered by PubFactory
  • [34.232.63.94]
  • 34.232.63.94
Close
Edit

Character limit 500/500

@!

Character limit 500/500